Android app Apple app link

In Lilly vs Novo obesity drug battle, Trump price talks grab focus

By Yahoo! Finance   |   1 month ago
In Lilly vs Novo obesity drug battle, Trump price talks grab focus

Eli Lilly and Novo Nordisk are preparing to release Q3 results amid high-stakes price talks with President Trump. Lilly is favored over Novo due to stronger trial data and market presence, while Novo faces internal challenges.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.